313 related articles for article (PubMed ID: 33914780)
1. Risk factors for COVID-19 mortality: The effect of convalescent plasma administration.
Salazar MR; González SE; Regairaz L; Ferrando NS; González Martínez VV; Carrera Ramos PM; Muñoz L; Pesci SA; Vidal JM; Kreplak N; Estenssoro E
PLoS One; 2021; 16(4):e0250386. PubMed ID: 33914780
[TBL] [Abstract][Full Text] [Related]
2. [Convalescent plasma therapy in COVID-19 patients, in the Province of Buenos Aires].
González SE; Regairaz L; Ferrando NS; González Martínez VV; Salazar MR; Estenssoro E
Medicina (B Aires); 2020; 80(5):417-424. PubMed ID: 33048783
[TBL] [Abstract][Full Text] [Related]
3. Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia.
González SE; Regairaz L; Salazar MR; Ferrando NS; González Martínez VV; Carrera Ramos PM; Pesci SA; Vidal JM; Kreplak N; Estenssoro E
J Investig Med; 2022 Jun; 70(5):1258-1264. PubMed ID: 35135872
[TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.
Estenssoro E; Loudet CI; Ríos FG; Kanoore Edul VS; Plotnikow G; Andrian M; Romero I; Piezny D; Bezzi M; Mandich V; Groer C; Torres S; Orlandi C; Rubatto Birri PN; Valenti MF; Cunto E; Sáenz MG; Tiribelli N; Aphalo V; Reina R; Dubin A;
Lancet Respir Med; 2021 Sep; 9(9):989-998. PubMed ID: 34224674
[TBL] [Abstract][Full Text] [Related]
7. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.
Kocayiğit H; Demir G; Karacan A; Süner KÖ; Tomak Y; Yaylacı S; Dheir H; Kalpakci Y; Erdem AF
Transfus Apher Sci; 2021 Aug; 60(4):103148. PubMed ID: 33962885
[TBL] [Abstract][Full Text] [Related]
8. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
[TBL] [Abstract][Full Text] [Related]
9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
10. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
11. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
[TBL] [Abstract][Full Text] [Related]
12. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B
PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114
[TBL] [Abstract][Full Text] [Related]
13. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.
Misset B; Hoste E; Donneau AF; Grimaldi D; Meyfroidt G; Moutschen M; Compernolle V; Gothot A; Desmecht D; Garigliany M; Najdovski T; Laterre PF
BMC Pulm Med; 2020 Dec; 20(1):317. PubMed ID: 33287790
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma for COVID-19 in the intensive care unit.
Rollas K; Emgin Ö; Çalışkan T; K Güldoğan I; Zincircioğlu Ç; Ersan G; Sahar İ; Sarıtaş A; Uzun U; Senoğlu N
Anaesthesiol Intensive Ther; 2021; 53(5):398-402. PubMed ID: 35100797
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of convalescent plasma in Indian patients with COVID-19.
Budhiraja S; Dewan A; Aggarwal R; Singh O; Juneja D; Pathak S; Singh YP; Gupta A; Rai R; Indrayan A; Jha V; Naithani R
Blood Cells Mol Dis; 2021 May; 88():102548. PubMed ID: 33621948
[TBL] [Abstract][Full Text] [Related]
17. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression.
Snow TAC; Saleem N; Ambler G; Nastouli E; McCoy LE; Singer M; Arulkumaran N
Br J Anaesth; 2021 Dec; 127(6):834-844. PubMed ID: 34579942
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
